SecBot SecBot

INKT drug pipeline

MiNK Therapeutics, Inc. · 2 rated drugs
$9.35
+0.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2
Time to marketagenT-797 is not approved in any market. The most advanced program is the randomized Phase 2 ARDS trial (C-1300-02), with data expected in 2H2027. Even with positive data, additional trials and regulatory review would be needed before any potential approval, likely several years away.

agenT-797 Updated Nov 11

What to watch

The next hard catalyst is the U.S. dosing initiation in the randomized Phase 2 ARDS trial (C-1300-02), expected before year-end 2026, with topline data not expected until 2H2027. In the nearer term, watch for any updates on the ARPA-H BoSS program funding allocation and enrollment progress in the ongoing Phase 2 colorectal cancer trial. The company's $7.5M cash position and $1.3M quarterly operating burn suggest a financing event may be needed within 2-3 quarters to fund the ARDS trial through readout.

Bull case
  • agenT-797 generated first-ever pre-commercial product revenue of $0.2M in Q3 2026 from a named-patient access program in Brazil, demonstrating real-world demand and a potential commercial pathway.
  • The drug was selected for the ARPA-H BoSS program (Draper-led team, up to $87M in program-wide funding), providing non-dilutive support and government validation of the platform.
  • Analyst consensus is strongly bullish: 7 analysts rate the stock a Buy or Strong Buy (mean target $44 vs $10.22 current price, implying ~339% upside), with B. Riley reiterating Buy as recently as October 21, 2026.
Bear case
  • Cash runway is limited: MiNK ended Q3 2026 with only $7.5M in cash, and the $1.3M quarterly operating burn suggests the company may need to raise capital within 2-3 quarters to fund the randomized ARDS trial through its 2H2027 readout, creating dilution risk.
  • The randomized Phase 2 ARDS trial (C-1300-02) is early-stage with no placebo-controlled data yet; early positive signals from tiny patient numbers may not replicate in a controlled setting.
  • CEO Jennifer Buell sold $73K worth of stock on October 12, 2026, and UBS trimmed its INKT position by ~68% in Q2 2026, signaling insider/institutional caution.
● neutral
Impact
PhasePreclinical
Time to marketSeveral years away, if ever. MiNK-215 remains in preclinical research with no IND filed or clinical trial initiated. An investigational new drug (IND) application and Phase 1 trial initiation would be the next milestones, which typically require 1-2 years of additional preclinical work plus regulatory review.

MiNK-215 Updated Nov 14

What to watch

MiNK-215 is a preclinical asset with no near-term binary catalyst. Watch for any IND filing or first-in-human clinical trial initiation, which could take 12-24 months. The stock's near-term value driver remains the Phase 2 ARDS trial of agenT-797 (data expected 2H2027).

Bull case
  • MiNK-215 is an off-the-shelf, allogeneic cell therapy (no patient-specific manufacturing delay) with a dual mechanism: FAP-targeting CAR to attack cancer-associated fibroblasts in the tumor microenvironment, plus IL-15 armoring for persistence.
  • Recent SITC 2026 preclinical data showed MiNK-215 and agenT-797 act as 'living senolytics,' clearing senescent tumor cells and fibroblasts left after chemotherapy, a novel application in oncology.
  • Analyst consensus is strongly bullish: 7 buy/strong-buy ratings vs 1 hold, with a mean price target of $44 (371% implied upside from the $9.34 close) per HC Wainwright and B. Riley.
Bear case
  • MiNK-215 is preclinical only; it has not entered clinical trials and faces a long, uncertain path to proof-of-concept in humans.
  • The company's cash position of $7.5M (as of Q3 2026) is limited and may require dilutive financing to fund both the lead program (agenT-797 Phase 2 ARDS trial) and early-stage pipeline work.
  • CEO Jennifer Buell sold $73K in stock on October 12, 2026, and UBS trimmed its INKT position by 70% in Q3 2026, indicating insider/institutional caution.